American Portfolios Advisors Alaunos Therapeutics, Inc. Transaction History

American Portfolios Advisors

$2.36 Trillion
Q3 2022

A detailed history of American Portfolios Advisors transactions in Alaunos Therapeutics, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 2,100 shares of TCRT stock, worth $4,788. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,100

Holding current value

$4,788

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Mar 17, 2023	BUY	$1.04 - $322.5 $2,184 - $677,250	2,100 New	2,100 $3.61 Million
Q2 2021 Mar 22, 2023	SELL	$2.63 - $3.67 $789 - $1,101	-300 Reduced 14.29%	1,800 $4.75 Million
Q1 2021 Mar 22, 2023	SELL	$2.82 - $5.6 $846 - $1,680	-300 Reduced 14.29%	1,800 $6.48 Million
Q4 2020 Mar 22, 2023	SELL	$2.09 - $3.09 $1,672 - $2,472	-800 Reduced 38.1%	1,300 $3.28 Million
Q3 2020 Mar 22, 2023	SELL	$2.39 - $3.43 $1,912 - $2,744	-800 Reduced 38.1%	1,300 $3.28 Million
Q1 2020 Mar 24, 2023	SELL	$1.9 - $4.98 $1,520 - $3,984	-800 Reduced 38.1%	1,300 $3.19 Million
Q4 2019 Mar 24, 2023	SELL	$3.95 - $5.35 $3,160 - $4,280	-800 Reduced 38.1%	1,300 $6.14 Million
Q3 2019 Mar 24, 2023	SELL	$4.13 - $6.94 $16 - $27	-4 Reduced 0.31%	1,300 $5.56 Million
Q2 2019 Mar 24, 2023	SELL	$3.98 - $6.2 $3,168 - $4,935	-796 Reduced 37.9%	1,304 $7.6 Million
Q4 2018 Mar 24, 2023	BUY	$1.61 - $3.62 $2,093 - $4,706	1,300 Added 32500.0%	1,304 $2.44 Million
Q3 2018 Mar 24, 2023	SELL	$2.26 - $3.27 $4,736 - $6,853	-2,096 Reduced 99.81%	4 $13,000
Q1 2018 Mar 24, 2023	SELL	$3.46 - $5.14 $7,252 - $10,773	-2,096 Reduced 99.81%	4 $16,000
Q4 2017 Mar 24, 2023	SELL	$4.0 - $6.54 $8,384 - $13,707	-2,096	4 $17,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $493M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Account

American Portfolios Advisors Alaunos Therapeutics, Inc. Transaction History